Monash IVF Group Ltd (AU:MVF)
ASX:MVF
Top Page
Monash IVF Group Ltd
(Sydney:MVF)
Select Model
Select Model
Rating:67Neutral
Price Target:
AU$0.71
▲(10.16% Upside)
Action:ReiteratedDate:11/25/25
Monash IVF Group Ltd's strong valuation metrics, including a low P/E ratio and high dividend yield, are the most significant strengths. However, the overbought technical indicators and weak cash flow position present notable risks. The absence of recent earnings call data and corporate events limits further insights.
Positive Factors
Revenue Growth
A 74.5% revenue jump indicates expanding patient volumes, higher clinic utilisation and stronger service mix. Sustained top-line growth supports scale benefits across clinics and labs, enabling reinvestment in capacity and improving long-term competitive position in fertility services.
Negative Factors
Free Cash Flow Decline
A near-total collapse in free cash flow materially reduces financial flexibility for capex, acquisitions or shareholder returns. Over months this can force higher external financing, delay strategic investments, and increase vulnerability if operating conditions weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A 74.5% revenue jump indicates expanding patient volumes, higher clinic utilisation and stronger service mix. Sustained top-line growth supports scale benefits across clinics and labs, enabling reinvestment in capacity and improving long-term competitive position in fertility services.
Read all positive factors
Monash IVF Group Ltd (MVF) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$249.37M
Dividend Yield6.22%
Average Volume (3M)2.18M
Price to Earnings (P/E)10.0
Beta (1Y)1.18
Revenue Growth6.65%
EPS GrowthN/A
CountryAU
Employees997
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.02
Shares Outstanding389,634,830
10 Day Avg. Volume1,374,502
30 Day Avg. Volume2,181,726
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.12
Price to Sales (P/S)1.01
P/FCF Ratio588.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.78Price Target Upside21.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.05
Revenue Forecast (FY)AU$266.46M
Monash IVF Group Ltd Business Overview & Revenue Model
Company Description
Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. It also provides tertiary...
How the Company Makes Money
MVF generates revenue primarily by providing fertility treatment and related patient services through its clinics and laboratories. Key revenue streams include: (1) Clinical fertility services: fees earned from patient treatment cycles and consult...
Monash IVF Group Ltd Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 269.39M | 271.92M | 254.96M | 213.59M | 192.29M | 183.60M |
| Gross Profit | 75.88M | 90.31M | 85.50M | 63.41M | 57.22M | 57.66M |
| EBITDA | 40.69M | 53.01M | 10.78M | 48.49M | 43.16M | 51.21M |
| Net Income | 15.16M | 25.01M | -6.53M | 21.84M | 18.41M | 25.15M |
Balance Sheet | ||||||
| Total Assets | 510.21M | 492.61M | 508.47M | 421.89M | 387.10M | 356.17M |
| Cash, Cash Equivalents and Short-Term Investments | 8.14M | 9.43M | 11.33M | 8.01M | 7.87M | 8.76M |
| Total Debt | 281.81M | 180.31M | 135.37M | 100.04M | 77.23M | 45.99M |
| Total Liabilities | 252.26M | 242.19M | 261.81M | 146.82M | 117.20M | 87.73M |
| Stockholders Equity | 253.91M | 246.28M | 241.91M | 273.20M | 267.92M | 266.19M |
Cash Flow | ||||||
| Free Cash Flow | 9.23M | 468.00K | 31.70M | 10.16M | 19.51M | 33.30M |
| Operating Cash Flow | 23.21M | 12.90M | 52.52M | 37.95M | 31.28M | 43.25M |
| Investing Cash Flow | -18.93M | -17.43M | -38.80M | -40.51M | -15.16M | -11.21M |
| Financing Cash Flow | -1.33M | 2.67M | -10.39M | 1.51M | -17.02M | -38.35M |
Monash IVF Group Ltd Technical Analysis
Negative
0.64
Price Trends
0.68
Negative
0.71
Negative
0.71
Negative
Market Momentum
-0.01
Negative
42.02
Neutral
41.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVF, the sentiment is Negative. The current price of 0.64 is below the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.68, and below the 200-day MA of 0.71, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 42.02 is Neutral, neither overbought nor oversold. The STOCH value of 41.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MVF.
Monash IVF Group Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$10.07B | 10.64 | 6.39% | 4.69% | 9.44% | -0.37% | |
67 Neutral | AU$249.37M | 10.00 | 6.06% | 6.22% | 6.65% | ― | |
59 Neutral | AU$389.96M | 23.92 | 16.35% | 4.60% | 6.73% | 37.16% | |
55 Neutral | AU$898.24M | 26.42 | 2.05% | 2.65% | 33.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$424.79M | -5.40 | -67.21% | ― | -23.02% | 33.11% |
* Healthcare Sector Average
AU:MVF
Monash IVF Group Ltd
0.64
-0.45
-41.28%
AU:HLS
Healius Limited
0.59
-0.48
-44.86%
AU:SHL
Sonic Healthcare Limited
20.38
-4.47
-17.98%
AU:IDX
Integral Diagnostics Ltd.
2.41
0.14
6.31%
AU:ACL
Australian Clinical Labs Ltd
2.06
-0.79
-27.82%
Monash IVF Group Ltd Corporate Events
Monash IVF Appoints Interim CFO to Support Executive Transition
Mar 25, 2026
Monash IVF Group has appointed Birol Akdogan as Interim Chief Financial Officer, effective 26 March 2026, bringing in a seasoned finance leader with experience across ASX-listed and private organisations such as Ansell Limited and DBG Health. The ...
Monash IVF outlines 1H26 performance under strict disclaimer
Feb 26, 2026
Monash IVF Group has released a presentation outlining its activities and financial performance for the first half of fiscal 2026, emphasising that the material is general background information and may change. The group highlights that its report...
Monash IVF Declares Interim Dividend for Half-Year to December 2025
Feb 25, 2026
Monash IVF Group Ltd has declared an ordinary dividend of AUD 0.012 per fully paid share, relating to the six-month period ended 31 December 2025. The dividend will trade ex-dividend on 4 March 2026, with a record date of 5 March 2026 and payment ...
Monash IVF Profit Slides on Higher Costs Despite Meeting Guidance
Feb 25, 2026
Monash IVF Group reported half-year 2026 revenue of $137.9 million, down 1.8% year-on-year, with underlying EBITDA falling 15.3% to $30.2 million and underlying net profit dropping 34% to $10.4 million, albeit at the upper end of previously update...
Monash IVF Group Names Rebecca Dean as Company Secretary and General Counsel
Jan 30, 2026
Monash IVF Group has appointed Rebecca Dean as its new Company Secretary and General Counsel, effective 4 March 2026, strengthening its governance and legal capabilities across its assisted reproductive and women’s health services operations...
Monash IVF CFO Malik Jainudeen Resigns, Formal Search for Successor Underway
Jan 27, 2026
Monash IVF Group has announced the resignation of its Chief Financial Officer and Company Secretary, Malik Jainudeen, who will remain with the company until the end of April 2026 before taking up a role with another organisation. The board has com...
Monash IVF Appoints Victoria Atkinson to Board with No Initial Shareholding
Jan 6, 2026
Monash IVF Group Limited has announced the appointment of Victoria Atkinson as a director of the company, effective 5 January 2026. According to the initial director’s interest notice lodged with the ASX, Atkinson currently holds no relevant...
Monash IVF Director Reduces Indirect Stake After Super Platform Closure
Dec 29, 2025
Monash IVF Group has disclosed a change in director Catherine Ann Aston’s shareholding following the lodgement of an Appendix 3Y notice. Aston has disposed of 75,000 indirectly held ordinary shares in the company, leaving her with a direct h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.